AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01470157
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline (placebo) in addition to Midazolam 0.5mg/kg as oral suspension
Trial: NCT01306292
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is normal saline 0.9% for injection used as the comparator administered at 4.8 mL (same dose as SonoVue)
Trial: NCT00353002
Drug: Maxilene (4% Liposomal Lidocaine)
RxNorm normalized name: Maxiclens
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02814656
Drug: AZD8871
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple inhaled doses of AZD8871 will be administered via single dose dry powder inhaler (DPI). Each subject will receive a single inhaled dose of AZD8871 on Day 1 and then single once daily inhalations of AZD8871 will be administered for 12 days from Day 5 until Day 16.
Trial: NCT02814656
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple inhaled doses of placebo powder will be administered via single dose DPI. Each subject will receive a single inhaled dose of placebo on Day 1 and then single once daily inhalations of placebo will be administered for 12 days from Day 5 until Day 16.
Trial: NCT01464879
Drug: Testosterone Gel (FE 999303)
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02563782
Drug: tacrolimus and mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Immunosuppressive Agents
Trial: NCT02563782
Drug: Placebo tacrolimus and mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: placebo
Trial: NCT01228214
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 5mg/daily for 12 months
Trial: NCT01228214
Drug: amiloride
RxNorm normalized name: Amiloride
DrugBank: Amiloride (DB00594)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5mg/daily for 12 months
Trial: NCT03807583
Drug: Aminoven 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After randomization to the visit Day 60, two months after patients inclusion (Visit Day 0) and one month after clinical examination (Visit Day 30), patients will be assigned to a group:~* group A: RENORAL® product~* group B: AMINOVEN® 10% product~* group C: control group (without intradialytic supplementation)~Patients will consume the products and will be followed for 3 months, one visit per month (Day 90, Day 120, Day 150). Protocol visits are included in the patient's course of care.
Trial: NCT01455480
Drug: RPh201, botanical drug product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical
Trial: NCT01193101
Drug: LCZ696
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCZ696
Trial: NCT01193101
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo to LCZ696
Trial: NCT02347085
Drug: Placebo MDI
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01192880
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive bitopertin matching placebo once daily for 56 weeks.
Trial: NCT01192880
Drug: Antipsychotics
RxNorm normalized name: ANTIPSYCHOTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will continue to receive their stable antipsychotic regiment throughout the study. Study protocol does not specify any particular antipsychotic drug and regimen.
Trial: NCT02834819
Drug: 3% Nebulized Hypertonic Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03959293
Drug: FOLFIRI Protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Irinotecan: 180 mg/m² by 2-hour IV infusion,~* Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) by 2-hours IV infusion,~* 5-FU bolus: 400 mg/m² by 10-minutes IV bolus,~* Continuous 5-FU: 2400 mg/m² by 46-hour IV infusion
Trial: NCT00363584
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01465009
Drug: Acetylsalicylic acid (Aspirin, BAYE4465)
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single Administration of 2 tablets Acetylsalicylic acid (500 mg each); in addition, 2 tablets matching placebo to Paracetamol
Trial: NCT01465009
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Administration of 2 tablets matching Placebo to Acetylsalicylic Acid together with 2 tablets matching placebo to Paracetamol
Trial: NCT01240863
Drug: Hydrocodone ER
RxNorm normalized name: hydrocodone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the open-label, titration period, all participants were administered hydrocodone ER tablets at dosages of 15, 30, 45, 60, or 90 mg every 12 hours to identify a dosage deemed successful for managing their pain.~Hydrocodone ER was taken by participants randomized to the hydrocodone ER treatment arm during the double-blind treatment period at the dose level identified during the titration period.~Participants were instructed to take tablets with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating.
Trial: NCT01240863
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching the active drug dose identified during the titration period was taken by participants randomized to the placebo treatment arm during the double-blind treatment period.~Participants were instructed to take intervention with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating.
Trial: NCT01730872
Drug: Prednisolone Sodium Phosphate Ophthalmic Solution 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop in each eye, four times/day for 4 days.
Trial: NCT01730872
Drug: Tears Naturale II Ophthalmic Solution
RxNorm normalized name: Tears Naturale Ophthalmic Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one drop in each eye, four times/ day (QID) for 4 days
Trial: NCT00298636
Drug: adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03768427
Drug: Placebo for FDC EZ/Ator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single placebo tablet administered orally QD for 84 days
Trial: NCT01644643
Drug: Best Available Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to receive Best Available Therapy will receive the best available standard of care (SOC) anti-infective therapy for their infection administered in accord with approved local label recommendation
Trial: NCT02756403
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg
Trial: NCT02756403
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg
Trial: NCT02756403
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pills will be given before the uterine aspiration. Antibiotics will be given after the uterine aspiration.
Trial: NCT00613431
Drug: CS8080
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS-8080 tablets will be administered once daily at doses of 1, 3, 10, 20, 50 and 100 mg.
Trial: NCT00613431
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Some subjects will receive matching placebo instead of CS-8080.
Trial: NCT02471313
Drug: [18F] FMISO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[18F\] Fluromisonidazole, 1 h-(3-\[18F\]-fluro-2hydroxyl-propy10-2-nitro-imidazaole is an investigational positron emission tomography (PET) radiopharmaceutical for injection and used to visualize hypoxia imaging agent. Each patient will receive up to 10 mCi of \[18F\] FMISO PET imaging post TACE procedure.
Trial: NCT00529269
Drug: Enteric-Coated Mycophenolate Sodium (EC-MPS)
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02850978
Drug: Spiolto
RxNorm normalized name: Stiolto
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00844103
Drug: AZD8566
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10ml oral solution administered once a day over 10 days. Specific dose will be selected by the safety review committee
Trial: NCT00844103
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10ml oral solution administered once a day over 10 days.
Trial: NCT01649713
Drug: Fluval AB vaccination
RxNorm normalized name: Crotalidae immune F(ab')2 Injection [Anavip]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccination with Fluval AB suspension for injection
Trial: NCT00561522
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1,250 mg/m2 twice daily on days 1-14, followed by a 7-day drug-free interval. Treatment repeats every 21 days. The above cycle is repeated for 4-6 times.If disease recurrence or unacceptable toxicity or other criteria for withdrawal are met, treatment will be stopped.
Trial: NCT03020407
Drug: Antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prompt empirical antibiotics will be given to the patients within one hour before the treatment allocation.
Trial: NCT03020407
Drug: Vasopressor
RxNorm normalized name: Vasopressor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The threshold to the need of a vasopressor is set at mean arterial pressure below 65 mmHg if a patient's condition does not response to the fluid therapy.
Trial: NCT03129542
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses taken every 8 hours.
Trial: NCT00363311
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT01080417
Drug: Mycophenolate Mofetil Capsule 250 mg
RxNorm normalized name: mycophenolate mofetil Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
Trial: NCT02629861
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1.5 mL pre-filled syringes identical in appearance to active intervention. Study drug was administered at the clinical site.
Trial: NCT01685684
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, divided into 2 doses, q12h
Trial: NCT01629615
Drug: BKM120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BKM120 oral capsules. 100 mg daily in cycles of 28 days, until disease progression
Trial: NCT00895830
Drug: APD405
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT03973957
Drug: Fentanyl Citrate
RxNorm normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administration of intravenous fentanyl prior to talc slurry instillation in order to avoid pain associated with talc slurry application
Trial: NCT00895830
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT00707473
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03658850
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: for the placebo group will receive one tablet or equivalent volume of enteral solution of inert substance, identical to the hydrochlorothiazide presentations, every 12 hours until day 3
Trial: NCT04442269
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT01558388
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One vaginal tablet daily for 10 days.
Trial: NCT04729790
Drug: PRIM-DJ2727
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral FMT capsules
Trial: NCT03005340
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bazedoxifene 20 mg
Trial: NCT03005340
Drug: Treatment BC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bazedoxifene 20 mg, Cholecalciferol granule 10 mg
Trial: NCT00570843
Drug: New PEG based artificial tear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1, 2, (in the eye) Instill one drop in the left eye or right eye four times daily (can be used more frequently if needed)
Trial: NCT00570843
Drug: Optive
RxNorm normalized name: optive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1, 2, (in the eye) Instill one drop in the left eye or right eye four times daily (can be used more frequently if needed)
Trial: NCT01850953
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02108886
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: empty capsule filled with sugar
Trial: NCT02239926
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01334554
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No active drug
Trial: NCT04099277
Drug: LY3435151
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT02393859
Drug: Vincrisitne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/m\^2/day IV on Days 1 and 6
Trial: NCT02393859
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 g/m\^2 IV over 36 hours on Day 1
Trial: NCT04754763
Drug: Dentin-Bonding Agents
RxNorm normalized name: SKIN BOND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3M ESPE Scotchbond™ Universal Adhesive systems is a seventh generation single-bottled one-step self-etch adhesive system.
Trial: NCT04032821
Drug: Alkotinib（300mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. First empty stomach, after the meal.2. After eating first, after fasting.
Trial: NCT01720030
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo therapy to safeguard blinding
Trial: NCT00527228
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03423121
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be given four capsules of the placebo twice daily.
Trial: NCT03568812
Drug: Rillus®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible subjects will be divided into 2 groups randomly (Rillus® or placebo). The colour, smell, flavour, and size of the chewing tablet are the same between active and placebo drugs. Subjects will consume the tablet once daily at night for 12 weeks.
Trial: NCT00692003
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25-400 mg Zonisamide Placebo capsules orally once daily in the evening.~Maximum study duration of 28 weeks comprising:~Baseline Period (Week-8/-4 to Week 0) no treatment~Titration Period (Week 0 to Week 4) \<12 years old: 1 mg/kg Zonisamide Placebo; \>= 12 years old: 50 mg Zonisamide Placebo capsules daily titrated weekly until a dose of 5 mg/kg or 300 mg was reached by Week 4~Maintenance Period (Week 4 to Week 16) dose from Week 4 to be maintained (4 mg/kg or 200 mg in the event of dose limiting adverse events)~Down Titration Period (4 weeks)
Trial: NCT03289143
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo doses of Semorinemab given intravenously (IV).
Trial: NCT03289143
Drug: [18F]GTP1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[18F\]GTP1 will be administered as a solution for intravenous (IV) use, as part of positron emission tomography (PET) imaging.
Trial: NCT00305877
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally
Trial: NCT00140023
Drug: Azithromycin microspheres 2.0 single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05017870
Drug: KSR-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (0 day) eye drops received one drop to both eyes once a day (1\~5 day) eyedrops recieved one drop to both eyes four times a day
Trial: NCT05017870
Drug: KSR-004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (0 day) eye drops received one drop to both eyes once a day (1\~5 day) eyedrops recieved one drop to both eyes four times a day
Trial: NCT05017870
Drug: KSR-001-02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KSR-001-02
Trial: NCT05017870
Drug: KSR-001-03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KSR-001-03
Trial: NCT00222976
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment allocation either A Naproxen PO + placebo PR or B Placebo PO + Naproxen PR
Trial: NCT03633357
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will take two placebo tablets daily, for seven days.
Trial: NCT00077974
Drug: SU011248
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50-mg orally taken daily for 4 weeks and off treatment for 2 weeks until progression or unacceptable toxicity
Trial: NCT00030147
Drug: Transdermal Estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 microgram per day transdermal estradiol
Trial: NCT00030147
Drug: Placebo skin patch and placebo tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matched placebo skin patch to transdermal estradiol and matched tablets to either Raloxifene or Rimostil
Trial: NCT02248896
Drug: Other angiotensin-receptor blockers (ARBs)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02248896
Drug: Angiotensin-converting enzyme inhibitors (ACEIs)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02248896
Drug: Other major antihypertensive medication classes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: e.g. beta-blockers, calcium channel blockers (CCBs), diuretics
Trial: NCT01056614
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01874392
Drug: Investigational inhaled insulin (Technosphere)
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: by MannKind Corp. IND 61,729
Trial: NCT02805790
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 weeks of treatment with placebo administered once daily subcutaneously
Trial: NCT04567524
Drug: LYN-005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LYN-005 (14 or 28 mg weekly) plus IR risperidone matched placebo.
Trial: NCT04274595
Drug: Generic antiretroviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg emtricitabine plus 245mg tenofovir diisopropyl fumarate for 7 days
Trial: NCT00057564
Drug: A (Thalidomide + Dexamethasone)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thalidomide 50mg/day + Dexamethasone 40mg
Trial: NCT00057564
Drug: B (Placebo + Dexamethasone)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + Dexamethasone 40mg
Trial: NCT02318017
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02953184
Drug: Pegylated Liposomal Doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35mg/m2 iv drop during the first 4 cycles every three week
Trial: NCT02953184
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600mg/m2 IV drop during the first 4 cycles every three week
Trial: NCT02953184
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60mg/m2 Doxorubicin IV drop during the first 4 cycles every three week
Trial: NCT00054587
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg/m², D1 and every 3 weeks
Trial: NCT00054587
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg/m², D1 and every 3 weeks
Trial: NCT01008618
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm or thigh and replaced every day.
Trial: NCT01008618
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch indistinguishable from one-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm or thigh and replaced every day.
Trial: NCT03509961
Drug: Myeloablative allogeneic HCT with a non-TBI conditioning regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myeloablative study regimen will consist of busulfan, fludarabine and thiotepa.~day -7: Fludarabine and Busulfan day -6: Fludarabine and Busulfan day -5: Fludarabine and Busulfan day -4: Fludarabine and Busulfan day -3: Fludarabine day -2: Thiotepa day -1: Rest Day 0: Transplant
Trial: NCT01385592
Drug: AFQ056
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01385592
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01130181
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo